JP2024531409A5 - - Google Patents

Info

Publication number
JP2024531409A5
JP2024531409A5 JP2024510434A JP2024510434A JP2024531409A5 JP 2024531409 A5 JP2024531409 A5 JP 2024531409A5 JP 2024510434 A JP2024510434 A JP 2024510434A JP 2024510434 A JP2024510434 A JP 2024510434A JP 2024531409 A5 JP2024531409 A5 JP 2024531409A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
seq
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024510434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531409A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/113739 external-priority patent/WO2023020621A1/en
Publication of JP2024531409A publication Critical patent/JP2024531409A/ja
Publication of JP2024531409A5 publication Critical patent/JP2024531409A5/ja
Pending legal-status Critical Current

Links

JP2024510434A 2021-08-20 2022-08-19 抗ccr8抗体およびその使用 Pending JP2024531409A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/113913 2021-08-20
CN2021113913 2021-08-20
PCT/CN2022/113739 WO2023020621A1 (en) 2021-08-20 2022-08-19 Anti-ccr8 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024531409A JP2024531409A (ja) 2024-08-29
JP2024531409A5 true JP2024531409A5 (cg-RX-API-DMAC7.html) 2025-08-26

Family

ID=85239303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024510434A Pending JP2024531409A (ja) 2021-08-20 2022-08-19 抗ccr8抗体およびその使用

Country Status (10)

Country Link
US (1) US20250019451A1 (cg-RX-API-DMAC7.html)
EP (1) EP4388009A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024531409A (cg-RX-API-DMAC7.html)
KR (1) KR20240046533A (cg-RX-API-DMAC7.html)
CN (1) CN118176210A (cg-RX-API-DMAC7.html)
AU (1) AU2022331786A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225986A1 (cg-RX-API-DMAC7.html)
IL (1) IL310938A (cg-RX-API-DMAC7.html)
MX (1) MX2024002238A (cg-RX-API-DMAC7.html)
WO (1) WO2023020621A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
AU2023319869A1 (en) * 2022-08-04 2025-02-20 Beone Medicines I Gmbh Anti-ccr8 antibodies and methods of use
CA3265264A1 (en) 2022-08-19 2024-02-22 Fibrogen, Inc. CCR8 ANTIBODIES AND THEIR USES
CN120303296A (zh) * 2022-10-02 2025-07-11 瑞美德生物医药科技有限公司 C-c趋化因子受体8型(ccr8)拮抗剂抗体
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ccr8を抗原として認識する二重特異性抗体
AU2024305430A1 (en) * 2023-06-12 2026-01-22 Nanjing Probio Biotech Co., Ltd. Antibody binding to human ccr8 and the use thereof
KR20260070101A (ko) * 2023-07-07 2026-05-18 치루 파머수티컬 컴퍼니 리미티드 항-인간 ccr8 단클론 항체의 약학적 제제 및 이의 용도
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗fap-light融合蛋白及其用途
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
CN119371535B (zh) * 2024-09-20 2025-07-11 百济神州(上海)生物科技有限公司 抗ccr8抗体及其用途
CN119841954B (zh) * 2025-03-12 2025-11-04 上海百英生物科技股份有限公司 一种抗人ccr8单克隆抗体及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
BR112021011431A2 (pt) * 2018-12-27 2021-11-23 Univ Osaka Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
AU2021205877B2 (en) * 2020-01-06 2024-06-20 Vaccinex, Inc. Anti-CCR8 antibodies and uses thereof
TWI890283B (zh) * 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
JP7610302B2 (ja) * 2020-08-28 2025-01-08 ハーバー・バイオメド・(シャンハイ)・カンパニー・リミテッド Ccr8抗体及びその用途

Similar Documents

Publication Publication Date Title
IL310938A (en) Anti-CCR8 antibodies and their uses
JP2021514664A5 (cg-RX-API-DMAC7.html)
KR20220110177A (ko) 항인간 클라우딘 18.2 항체 및 그의 적용
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
JP2021516057A5 (cg-RX-API-DMAC7.html)
JP2021528047A5 (cg-RX-API-DMAC7.html)
JP2021526022A5 (cg-RX-API-DMAC7.html)
AU2020213579B2 (en) Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
JP2018526974A (ja) Pdl−1抗体、その医薬組成物及びその使用
JP2023540526A5 (cg-RX-API-DMAC7.html)
JP2015155431A (ja) Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物
TWI922434B (zh) 一種融合蛋白及其用途
JP2025038088A5 (cg-RX-API-DMAC7.html)
CN102027014A (zh) 用于治疗癌症的新抗体
JP2021517459A5 (cg-RX-API-DMAC7.html)
WO2024175093A1 (en) Antibodies, antigen-binding fragments and methods of use
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2022532991A5 (cg-RX-API-DMAC7.html)
JP2022526841A5 (cg-RX-API-DMAC7.html)
JP2025511135A5 (cg-RX-API-DMAC7.html)
CN117257934A (zh) 药物组合物及其用途
JP2023525991A5 (cg-RX-API-DMAC7.html)
TW202144005A (zh) 一種抗ox40抗體醫藥組成物及其用途
CN114933655B (zh) 抗cd123抗体及其应用
CN109053888B (zh) 一种抗人csf-1r单克隆抗体及其用途